TXMD TherapeuticsMD (TXMD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000025743
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter
TherapeuticsMD insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for TherapeuticsMD, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 14, 2025.
- -4.8% median (-4.8% mean) 90-day return after 2 previous buys.
- The trade is 36.2% of the 23,179 shares held after it.
- No other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thompson Tommy G bought about $14.0K of TXMD on Dec 23, 2025, the largest insider purchase at the company since 2022; 15 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 13, 2021.
- The trade is 2.2% of the 14,779 shares held after it.
- 1 other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thompson Tommy G bought about $325 of TXMD on Apr 14, 2025; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (2 buys, 5 sales), the last on Apr 10, 2025.
- +35.6% median (+35.6% mean) 90-day return after 2 previous buys.
- The trade is 0.7% of the 73,639 shares held after it.
- 1 other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Walker Marlan D bought about $490 of TXMD on Apr 14, 2025; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (1 buy, 5 sales), the last on Apr 9, 2025.
- The trade is 1.6% of the 73,149 shares held after it.
- 1 other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Walker Marlan D bought about $1.0K of TXMD on Apr 10, 2025; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Dec 7, 2023.
- The trade is 1.6% of the 71,982 shares held after it.
- 1 other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Walker Marlan D bought about $988 of TXMD on Apr 9, 2025; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.39 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 73% of Pharma & Biotech
Revenue
+71.6% year over year
more than 82% of Pharma & Biotech
Margin
-18.8% net margin
more than 59% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.3% of the float short (float per yahoo 2026-10-27) · 1.4 days to cover · settled 2026-10-15
below 85% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TXMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+35.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TXMD: institutional holders (13F)
13F holdings, latest reported quarter
1,192,191 sh
$2.6M
635,222 sh
$1.4M
353,697 sh
$781.7K
344,482 sh
$761.3K
342,447 sh
$756.8K
Congress trades in TXMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TXMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
TXMD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$37.6K position · as of 2026-06-30
0.0%
Enterprise Mergers and Acquisitions Fund
$2.2K position · as of 2026-06-30
0.0%
The Gabelli ABC Fund
$8.0K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$139.5K position · as of 2026-05-31
0.0%
Dimensional US Sustainability Core 1 ETF
$7.3K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$241.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TXMD financials
Revenue growth
+71.6%
XBRL, annual
Net margin
-18.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TXMD
| FY Dec 2025 | $3.0M |
| FY Dec 2024 | $1.8M |
| FY Dec 2023 | $1.3M |
| FY Dec 2022 | $70.0M |
| FY Dec 2021 | $87.0M |
| Jun 2026 | $869.0K |
| Mar 2026 | $724.0K |
| Dec 2025 | $893.0K |
| Sep 2025 | $784.0K |
| Jun 2025 | $952.0K |
| Mar 2025 | $393.0K |
| Dec 2024 | $667.0K |
| Sep 2024 | $547.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-6.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TXMD
| FY Dec 2025 | -18.8% |
| FY Dec 2024 | -123.9% |
| FY Dec 2023 | -789.4% |
| FY Dec 2022 | +160.1% |
| FY Dec 2021 | -198.3% |
| Jun 2026 | +17.8% |
| Mar 2026 | +13.1% |
| Dec 2025 | -69.3% |
| Sep 2025 | +19.4% |
| Jun 2025 | +57.9% |
| Mar 2025 | -166.2% |
| Dec 2024 | +37.8% |
| Sep 2024 | -111.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM TXMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$103.4M |
| FY Dec 2021 | -$142.7M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
3.45x
LongTermDebt as filed 2022-09-30 (45 months older than the period end) (includes the current portion); equity 2026-06-30
Debt to equity TXMD
| FY Dec 2025 | 3.48x |
| FY Dec 2024 | 3.42x |
| FY Dec 2023 | 3.20x |
| FY Dec 2022 | 2.66x |
| FY Dec 2021 | n/a |
| Jun 2026 | 3.45x |
| Mar 2026 | 3.47x |
| Dec 2025 | 3.48x |
| Sep 2025 | 3.41x |
| Jun 2025 | 3.43x |
| Mar 2025 | 3.50x |
| Dec 2024 | 3.42x |
| Sep 2024 | 3.45x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt TXMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.10x |
| FY Dec 2021 | -0.76x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-0.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TXMD
| FY Dec 2025 | -2.1% |
| FY Dec 2024 | -7.7% |
| FY Dec 2023 | -31.9% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.8% |
| Mar 2026 | +0.7% |
| Dec 2025 | -2.1% |
| Sep 2025 | +1.1% |
| Jun 2025 | -1.7% |
| Mar 2025 | -7.6% |
| Dec 2024 | -7.7% |
| Sep 2024 | -12.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-0.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TXMD
| FY Dec 2025 | -1.5% |
| FY Dec 2024 | -5.3% |
| FY Dec 2023 | -15.4% |
| FY Dec 2022 | +86.2% |
| FY Dec 2021 | -98.2% |
| Jun 2026 | -0.6% |
| Mar 2026 | +0.5% |
| Dec 2025 | -1.5% |
| Sep 2025 | +0.8% |
| Jun 2025 | -1.2% |
| Mar 2025 | -5.5% |
| Dec 2024 | -5.3% |
| Sep 2024 | -7.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital TXMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-11.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TXMD
| FY Dec 2025 | -13.2% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -21.3% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -11.9% |
| Mar 2026 | -11.6% |
| Dec 2025 | -13.2% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -18.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TXMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.46x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | 101.00x |
| Dec 2025 | n/a |
| Sep 2025 | 54.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$108.5M
market value at close 2026-10-27 on 2026-08-09 shares, plus LongTermDebt as filed 2022-09-30 (45 months older than the period end) (includes the current portion), minus cash 2025-03-31
Enterprise value TXMD
| FY Dec 2025 | $106.7M |
| FY Dec 2024 | $98.5M |
| FY Dec 2023 | $113.1M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $113.4M |
| Mar 2026 | $111.2M |
| Dec 2025 | $106.7M |
| Sep 2025 | $100.4M |
| Jun 2025 | $101.3M |
| Mar 2025 | $98.6M |
| Dec 2024 | $98.5M |
| Sep 2024 | $108.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield TXMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -195.4% |
| FY Dec 2021 | -1.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TXMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M |
| Gross profit | n/a | n/a | $1.3M | $68.6M |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M |
| Net income | -$569.0K | -$2.2M | -$10.3M | $112.0M |
| EPS (diluted) | -0.05 | -0.19 | -0.99 | 11.96 |
| Cash | n/a | $5.1M | $4.3M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
TXMD Stock Sonar score 5/7 axes
Find similar shapesCompareTXMD ranks highest on growth (82nd percentile) and profitability (80th), and lowest on financial health (5th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
